Clinical trials: CNS Tumor, Adult
Brain and Central Nervous System Tumors
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent…
- Trial name
- NCT00006119
- Testing
- hydroxyurea
- Where
- 5 sites in France
- Sponsor
- UNICANCER
Brain and Central Nervous System Tumors, Musculoskeletal Complications
Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma
RATIONALE: Testosterone gel may be effective in preventing or lessening muscle weakness caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade glioma.
- Trial name
- NCT00631137
- Testing
- testosterone gel applied to skin, whey powder protein
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioma
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00795665
- Testing
- bevacizumab, carmustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, Davis
Glioma, Malignant, Embryonal Tumor
Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas
The treatment of adolescents and young adults (AYA, 15 to 39 years) with malignant intra-axial CNS parenchymal tumors such as IDH-mutated gliomas, medulloblastomas and ependymomas is still not curative in all cases.
- Conditions
- Glioma, Malignant, Embryonal Tumor, Medulloblastoma, Ependymoma
- Trial name
- BZKF-AYA (NCT06323408)
- Testing
- Tissue, blood, cerebrospinal-spinal fluid
- Volunteers
- 72 people
- Sponsor
- University Hospital Regensburg
Brain and Central Nervous System Tumors
Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00331526
- Testing
- aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Brain and Central Nervous System Tumors
Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006258
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 3 sites in United States, Canada
- Sponsor
- Children's Hospital Los Angeles
Brain and Central Nervous System Tumors
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005855
- Testing
- carmustine, efaproxiral
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00268385
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide
- Where
- 17 sites in United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase I/II trial is studying the side effects and best dose of ixabepilone and how well it works in treating…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00045708
- Testing
- ixabepilone, pharmacological study, Anticonvulsant
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as temozolomide and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00099125
- Testing
- irinotecan hydrochloride, temozolomide, adjuvant therapy
- Where
- 118 sites in United States
- Volunteers
- 170 people
- Sponsor
- Radiation Therapy Oncology Group
Brain Metastases, Adult
A Neurocognitive Study in Patients With Brain Oligometastases Receiving Hypofractionated SRT
Background: For newly-diagnosed patients with brain metastasis, conventional whole-brain radiation therapy (WBRT) might still remain a common palliative management even for those with brain oligometastases.
- Trial name
- HF-SRT (NCT04805255)
- Testing
- Hypofractionated Stereotactic Radiotherapy
- Where
- 2 sites in Taiwan
- Volunteers
- 135 people
- Sponsor
- Chang Gung Memorial Hospital
Spinal Cord Injuries, Transverse Myelitis
The Impact of Expressive Emotional Writing on Facilitating Grief Resolution in Adults With Spinal Cord Injury
The aim of this study is to evaluate the therapeutic benefits of a 10-week online coach-guided EEWP on psychosocial health among adults with SCI.
- Trial name
- NCT06147258
- Testing
- expressive writing
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Ependymoma, Anaplastic Ependymoma
Carboplatin and Bevacizumab for Recurrent Ependymoma
The goal of this clinical research study is to learn if the combination of bevacizumab and carboplatin can help to control recurrent ependymoma. The safety of this drug combination will also be studied.
- Trial name
- NCT01295944
- Testing
- Carboplatin, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00004892
- Testing
- O6-benzylguanine, polifeprosan 20 with carmustine implant, conventional surgery
- Where
- 9 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Brain Tumors, Medulloblastoma
Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline
Radiation constitutes an integral component in the management of primary brain tumors in pediatric and young adults like medulloblastoma, ependymoma, low-grade glioma, pituitary tumors, etc.
- Conditions
- Brain Tumors, Medulloblastoma, Glioma, Ependymoma
- Trial name
- BIO-RIN (NCT06779487)
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Tata Memorial Centre
Brain Neoplasms
An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy.
- Trial name
- CheckMate548 (NCT02667587)
- Testing
- Nivolumab, Temozolomide, Radiotherapy
- Where
- 123 sites in United States, Australia and 17 more
- Volunteers
- 716 people
- Sponsor
- Bristol-Myers Squibb
Adult Central Nervous System Germ Cell Tumor, Adult Teratoma
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
This phase II trial studies how well palifosfamide works in treating patients with recurrent germ cell tumors. Drugs used in chemotherapy, such as palifosfamide, work in different ways to stop the growth of tumor cells, either by…
- Conditions
- Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Malignant Extragonadal Germ Cell Tumor, Malignant Extragonadal Non-Seminomatous Germ Cell Tumor
- Trial name
- NCT01808534
- Testing
- palifosfamide
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Indiana University
Breast Cancer
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with metastatic breast cancer (MBC).
- Trial name
- CONTESSA TRIO (NCT03952325)
- Testing
- Tesetaxel, Nivolumab, Pembrolizumab
- Where
- 12 sites in United States, Singapore and 1 more
- Volunteers
- 294 people
- Sponsor
- Odonate Therapeutics, Inc.
Central Nervous System Tumors
Bevacizumab in Recurrent Grade II and III Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- TAVAREC (NCT01164189)
- Testing
- Bevacizumab, Temozolomide
- Where
- 39 sites in Austria, Belgium and 6 more
- Volunteers
- 155 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC